Paul Hastings
2014 - OncoMed Pharmaceuticals
In 2014, Paul Hastings earned a total compensation of $3.2M as Chairman, Chief Executive Officer & President at OncoMed Pharmaceuticals, a 28% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $234,740 |
|---|---|
| Option Awards | $1,809,556 |
| Salary | $469,480 |
| Stock Awards | $698,175 |
| Total | $3,211,951 |
Hastings received $1.8M in option awards, accounting for 56% of the total pay in 2014.
Hastings also received $234.7K in non-equity incentive plan, $469.5K in salary and $698.2K in stock awards.
Rankings
In 2014, Paul Hastings' compensation ranked 2,811th out of 13,032 executives tracked by ExecPay. In other words, Hastings earned more than 78.4% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,811 out of 13,032 | 78th |
Division Manufacturing | 996 out of 4,965 | 80th |
Major group Chemicals And Allied Products | 316 out of 1,690 | 81st |
Industry group Drugs | 246 out of 1,369 | 82nd |
Industry Pharmaceutical Preparations | 203 out of 1,042 | 81st |
Source: SEC filing on April 29, 2016.
Hastings' colleagues
We found two more compensation records of executives who worked with Paul Hastings at OncoMed Pharmaceuticals in 2014.